Claims for Patent: 8,796,307
✉ Email this page to a colleague
Summary for Patent: 8,796,307
Title: | Beta2-adrenoreceptor agonists |
Abstract: | Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. |
Inventor(s): | Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin Alec (Horsham, GB), Beattie; David (Horsham, GB) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 14/076,478 |
Patent Claims: |
1. A pharmaceutical composition comprising: (A) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one or a salt or solvate thereof, and
(B) a pharmaceutically acceptable carrier wherein the pharmaceutical composition is in the form of a capsule.
2. A pharmaceutical composition according to claim 1, wherein (A) and (B) contained therein are in inhalable form. 3. A pharmaceutical composition according to claim 2, wherein the inhalable form of (A) and (B) is a dry powder formulation. 4. A pharmaceutical composition according to claim 3 comprising a daily dose of (A). 5. A pharmaceutical composition according to claim 4, wherein the daily dose of (A) is from 1 .mu.g to 5000 .mu.g. 6. A pharmaceutical composition according to claim 1, wherein (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 7. A pharmaceutical composition according to claim 5, wherein (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. |